BSLN Basilea Pharmaceutica AG

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 14, 2025

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment.

David Veitch, Basilea’s Chief Executive Officer, stated: “We are pleased with the strong sales performance from our partner Pfizer, resulting in this first sales milestone for the Asia Pacific and China region this year, which significantly surpasses previous sales milestones for the region. This underscores the continued progress in making Cresemba available to increasing numbers of patients suffering from life-threatening invasive mold infections in this region.”

The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific region.

Cresemba is marketed in more than 70 countries. According to the latest available market data, total global in-market sales of Cresemba in the twelve-month period between October 2023 and September 2024 amounted to USD 533 million, a 20 percent growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.1

About Cresemba® (isavuconazole)

Cresemba, with the active ingredient isavuconazole, is an intravenous (i.v.) and oral azole antifungal. Basilea has entered into several license and distribution agreements for Cresemba covering approximately 115 countries. In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the European Union2, the United Kingdom3, the United States (US)4 and several additional countries including in the Asia Pacific region.5

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit .

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD



Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland
Phone
E-mail

This press release can be downloaded from .

References

  1. IQVIA Analytics Link, September 2024. In-market sales reported as moving annual total (MAT) in US dollar.
  2. European Public Assessment Report (EPAR) Cresemba:  [Accessed: March 13, 2025]
  3. Summary of Product Characteristics (SmPC) Cresemba:  [Accessed: March 13, 2025]
  4. Full US prescribing information:  [Accessed: March 13, 2025]
  5. The registration status and approved indications may vary from country to country.

Attachment



EN
14/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Basilea Pharmaceutica AG

 PRESS RELEASE

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien...

Starke Verkaufszahlen für Cresemba® (Isavuconazol) in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea aus Allschwil, 14. März 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die anhaltend guten Verkäufe des Antimykotikums Cresemba® (Isavuconazol) durch Basileas Lizenzpartner Pfizer Inc. in der Region Asien-Pazifik und China die Schwelle überschritten haben...

 PRESS RELEASE

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea Allschwil, Switzerland, March 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment. ...

 PRESS RELEASE

Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutli...

Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anstieg von Umsatz, Gewinn und operativem Cashflow Gesamtumsatz um 32 % auf CHF 209 Mio. gesteigertBetriebsgewinn auf CHF 61 Mio. verdreifachtOperativer Cashflow signifikant auf CHF 74 Mio. erhöht Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 18. Februar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, veröffentlichte heute die Finanze...

 PRESS RELEASE

Basilea reports strong 2024 full-year results with significant increas...

Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61mOperating cash flow significantly increased to CHF 74m Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 18, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2024. D...

 PRESS RELEASE

Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilenste...

Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilensteinzahlung von AKP an Basilea aus Allschwil, 05. Februar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) in Japan die Schwelle überschritten haben, durch welche die erste Umsatzmeilensteinzahlung von seinem Partner Asahi Kasei Pharma (AKP) in Höhe von rund CHF 1.2 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch